Search research articles
Contact Us
Filters
Showing results (151-160 of 165) with videos related to
Page
of 17
Sort By:
The Journal of Infectious Diseases
|
March 19, 2021
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, et al.
The Lancet Regional Health. Southeast Asia
|
August 24, 2023
High PrEP uptake, adherence, persistence and effectiveness outcomes among young Thai men and transgender women who sell sex in Bangkok and Pattaya, Thailand: findings from the open-label combination HIV prevention effectiveness (COPE) study
Brian W Weir, Andrea L Wirtz, Tareerat Chemnasiri, et al.
AIDS (London, England)
|
March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial
Trevor A Crowell, Justin Ritz, Lu Zheng, et al.
The Journal of Infectious Diseases
|
November 5, 2016
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)
Roy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
Annals of Internal Medicine
|
August 23, 2017
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial
Roy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
Lancet (London, England)
|
April 4, 2021
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Shahin Lockman, Sean S Brummel, Lauren Ziemba, et al.
The Lancet. HIV
|
October 28, 2023
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial
Gonasagrie Nair, Connie Celum, Daniel Szydlo, et al.
The New England Journal of Medicine
|
December 2, 2015
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Jean-Michel Molina, Catherine Capitant, Bruno Spire, et al.
The Journal of Infectious Diseases
|
March 18, 2022
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084
Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, et al.
Page
of 17
Search research articles
Search
Showing results (151-160 of 165) with videos related to
Sort By:
Page
of 17
The Journal of Infectious Diseases
|
March 19, 2021
Characterization of Human Immunodeficiency Virus (HIV) Infection in Cisgender Men and Transgender Women Who Have Sex With Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Beatriz Grinsztejn, Jessica M Fogel, et al.
The Lancet Regional Health. Southeast Asia
|
August 24, 2023
High PrEP uptake, adherence, persistence and effectiveness outcomes among young Thai men and transgender women who sell sex in Bangkok and Pattaya, Thailand: findings from the open-label combination HIV prevention effectiveness (COPE) study
Brian W Weir, Andrea L Wirtz, Tareerat Chemnasiri, et al.
AIDS (London, England)
|
March 15, 2024
Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial
Trevor A Crowell, Justin Ritz, Lu Zheng, et al.
The Journal of Infectious Diseases
|
November 5, 2016
Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305)
Roy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
Antimicrobial Agents and Chemotherapy
|
March 30, 2023
Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
Mark A Marzinke, Jessica M Fogel, Zhe Wang, et al.
Annals of Internal Medicine
|
August 23, 2017
Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Women: A Phase 2 Randomized Trial
Roy M Gulick, Timothy J Wilkin, Ying Q Chen, et al.
Lancet (London, England)
|
April 4, 2021
Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial
Shahin Lockman, Sean S Brummel, Lauren Ziemba, et al.
The Lancet. HIV
|
October 28, 2023
Adherence, safety, and choice of the monthly dapivirine vaginal ring or oral emtricitabine plus tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis among African adolescent girls and young women: a randomised, open-label, crossover trial
Gonasagrie Nair, Connie Celum, Daniel Szydlo, et al.
The New England Journal of Medicine
|
December 2, 2015
On-Demand Preexposure Prophylaxis in Men at High Risk for HIV-1 Infection
Jean-Michel Molina, Catherine Capitant, Bruno Spire, et al.
The Journal of Infectious Diseases
|
March 18, 2022
Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084
Susan H Eshleman, Jessica M Fogel, Estelle Piwowar-Manning, et al.
Page
of 17